Physician profile
John A Volpe
NPI 1063460624
$4,067.34
in general payments reported to CMS, 2019-2025
25 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $75.35 · 2021: $296 · 2022: $207 · 2023: $327 · 2024: $1,149 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $939.56 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $404.74 | 2019-2025 | Tremfya, Remicade, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.39 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $292.17 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Braintree Laboratories, INC. | $271.42 | 2019-2025 | Suflave, Sutab |
| Ardelyx, INC. | $244.32 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $211.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $141.15 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $125.94 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2024 | Airsupra |
| Sebela Pharmaceuticals INC. | $119.80 | 2020-2022 | |
| Pfizer INC. | $113.84 | 2019-2025 | |
| Lilly USA, LLC | $101.84 | 2024-2025 | Omvoh |
| Ani Pharmaceuticals, INC. | $82.68 | 2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $71.97 | 2023-2025 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $67.30 | 2024 | Idose |
| Qol Medical, LLC | $65.42 | 2025 | Sucraid |
| Celltrion USA INC. | $65.19 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $62.37 | 2021-2024 | Dificid |
| Celgene Corporation | $54.14 | 2023-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $46.81 | 2024-2025 | |
| Gilead Sciences, INC. | $45.47 | 2019 | |
| Aimmune Therapeutics, INC. | $19.35 | 2023 | |
| Shire North American Group INC | $16.42 | 2019 | |
| Lifenet Health | $16.03 | 2024 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Volpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.